Navigation Links
Portola Data on Its Novel Syk Inhibitors and Novel Universal Factor Xa Inhibitor Antidote to be Presented at 2008 American Society of Hematology (ASH) Meeting
Date:12/3/2008

SOUTH SAN FRANCISCO, Calif., Dec. 3 /PRNewswire/ -- Portola Pharmaceuticals, a biopharmaceutical company developing innovative drugs that provide significant advances in cardiovascular disease, inflammatory disease and cancer, today announced that data related to the Company's series of novel compounds that inhibit spleen tyrosine kinase (Syk) and its novel universal Factor Xa inhibitor antidote will be presented at the annual meeting of the American Society of Hematology (ASH) at the Moscone Center in San Francisco during December 6-9, 2008.

Portola's Syk inhibitor program is focused on developing specific oral inhibitors of this key signaling pathway, which modulate inflammation, certain cancers and thrombosis. The Company plans to study its compounds initially in rheumatoid arthritis and non-Hodgkin's Lymphoma and eventually intends to explore their potential in other inflammatory diseases and cancers. Portola is developing its universal Factor Xa inhibitor antidote to neutralize the effect of small molecule Factor Xa inhibitors in patients experiencing major bleeding and for patients undergoing emergent or elective surgery.

Details of the ASH presentations are below and full abstracts can be viewed on the ASH website at http://www.hematology.org.

Syk Inhibitor Program

"Specific Inhibition of Syk is Sufficient to Disrupt Proliferation and Survival of Non-Hodgkin's Lymphoma Cell Lines without Concomitant Inhibition of JAK" (abstract # 1794)

Saturday, December 6, 5:30 PM

Hall A (Moscone Center)

"PRT060318, a Novel Syk Inhibitor, Prevents Heparin-Induced Thrombocytopenia in a Transgenic Mouse Model" (abstract # 269)

Monday, December 8, 7:00 AM

3007-3009-3011 - West (Moscone Center)

"Specific Pharmacological Targeting of the Syk Kinase Activity in Platelets: A Nove
'/>"/>

SOURCE Portola Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Portola Pharmaceuticals Names William Lis Vice President of Business Development and Commercial Operations
2. Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation
3. Novel Technology Breaks Through Cancer Pain
4. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
5. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
6. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
7. New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA
8. NIST team develops novel method for nanostructured polymer thin films
9. GlaxoSmithKline Awarded U.S. Department of Defense Contract to Pursue Novel Antibacterial Research Program
10. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
11. European Expert Consortium Combines Forces to Develop a Novel Pandemic Influenza Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... SUMMERLAND, British Columbia , Feb. 27, 2015 ... ), a leader in synthetic biology, today announced it ... Fruits (OSF), the pioneering agricultural company behind the ... non-browning apple. Through the acquisition, Intrexon expands its food ... appetizing and convenient for consumers while providing economic benefit ...
(Date:2/27/2015)... 2015 Immunovaccine Inc. (“Immunovaccine”) (TSX: ... today announced that the U.S. Food and Drug ... designation and Phase I clinical trials of the ... mutual co-development agreement signed with Gilead Life Sciences. ... for the DPX-Survivac. , “We have been in ...
(Date:2/27/2015)... Brighton, Illinois (PRWEB) February 27, 2015 ... Matt Sims, General Manager of State Line Farms, received ... Award recognizes a producer, under the age of 35, ... , "It is an honor to win the Tomorrow's ... to discovering who won the Top Producer Award and ...
(Date:2/26/2015)... 26, 2015 S&P Capital IQ (MHFI) announced ... coverage on MabVax Therapeutics Holdings Inc . ... stage biotechnology company focused on the development of vaccine ... the treatment of cancer. MabVax has discovered a pipeline ... immune responses generated by patients who have been immunized ...
Breaking Biology Technology:Intrexon to Acquire Okanagan Specialty Fruits 2Intrexon to Acquire Okanagan Specialty Fruits 3Intrexon to Acquire Okanagan Specialty Fruits 4Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3Matt Sims Receives the 2015 Tomorrow’s Top Producer Horizon Award 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5
... PROCESSING AND STORAGE OF EQUINE ... TISSUE STEM CELLS, RANCHO CORDOVA, Calif., Feb. 27 ... of innovative products and,services that process and store adult ... has signed a formal agreement with,the UC Davis School ...
... to, pure cardiomyocytes and other novel ES ... discovery, toxicity testing, and ... (Seattle, WA) announced,today that it will distribute the full ... American life science research and drug,discovery market., (Logo: ...
... Anesiva,Inc. (Nasdaq: ANSV ) announced today that John ... the Susquehanna Financial Group,SIGnificant Investment Options in Healthcare Conference ... pm EDT., To access the live webcast or ... go to the Investors page, and click on Events.,Please ...
Cached Biology Technology:ThermoGenesis Subsidiary Vantus Announces Stem Cell Agreement With UC Davis Center For Equine Health 2ThermoGenesis Subsidiary Vantus Announces Stem Cell Agreement With UC Davis Center For Equine Health 3ThermoGenesis Subsidiary Vantus Announces Stem Cell Agreement With UC Davis Center For Equine Health 4ThermoGenesis Subsidiary Vantus Announces Stem Cell Agreement With UC Davis Center For Equine Health 5ReachBio Partners with Axiogenesis to Distribute Novel Cell-Based Products in North America 2ReachBio Partners with Axiogenesis to Distribute Novel Cell-Based Products in North America 3
(Date:1/22/2015)... 15, 2015  BellBrook Labs, a leader in high ... launch of a TR-FRET (time resolved Forster resonance ... Assay, a high throughput screening assay for glycosyltransferases ... allow for sensitive detection of hundreds of human ...
(Date:1/22/2015)... and POINT ROBERTS, Washington , ... source covering leading sectors including technology and tech stocks, releases ... marketplace featuring master pickpocket and security consultant Apollo Robbins ... stolen and talks about the Wocket™ biometric smart wallet, a ...
(Date:1/22/2015)... and Markets ( http://www.researchandmarkets.com/research/wxdglm/global_wearable ) has ... Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, ... report to their offering. , ... be worn on the user,s body and have ...
Breaking Biology News(10 mins):BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2
... German and Spanish . ... higher threat to its neighbour, Argentina, than vice versa. This ... Chile and the Helmholtz Centre for Environmental Research (UFZ) after ... species which occur in Chile on connecting roads leading to ...
... This release is available in German . ... diseases. The early detection of pathogens and the subsequent immune ... protective shield. However, the pathogens that cause plant diseases have ... cell wall reaction in plants. "One particularly ingenious attacker, powdery ...
... is the key to getting our ,body clocks, back in ... in insects has discovered a molecule essential to the process. ... at the impact of light on the circadian clocks (commonly ... novel molecule, QUASIMODO (QSM), which was intrinsically involved in relaying ...
Cached Biology News:Chile is more dangerous for Argentina than vice versa 2Chile is more dangerous for Argentina than vice versa 3TUM researchers discover a new switch in resistance to plant diseases 2Newly discovered molecule essential to resetting 'body clocks' 2
PC12 (rat phaeochromocytoma) cells Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
Peptide-affinity Purified Polyclonal Antibody to Olfactory Receptor, Family 2, Subfamily H, Member 3...
... Quality ISO 9001:2000 Certified ... All Precedures Validated, SOP's Training ... Process for All Procedures GLP Documentation Upon ... one stop shopping point for all your ...
Peptide-affinity Purified Polyclonal Antibody to Prolactin Releasing Hormone Receptor (GPR10)...
Biology Products: